P&G third quarter forecast
This article was originally published in The Rose Sheet
Executive Summary
Double-digit earnings growth anticipated in fiscal third quarter (ending March 31), Chief Financial Officer Clayt Daley tells investors at Merrill Lynch Global Consumer Products Conference March 19-20. Sales expected to grow in high single digits after negative currency impact, Procter & Gamble adds. Year-end sales expected to be an improvement over their 2% decline in 2001, but will not yet reach P&G's long-term goal of 4%-6% growth...
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.